Proactive Investors - Run By Investors For Investors

Beaufort Securities Breakfast Alert - Government to hold pensions talks with Carillion

Beaufort Securities Breakfast Alert - Government to hold pensions talks with Carillion


The FTSE-100 finished yesterday's session 0.19% higher at 7,762.94, whilst the FTSE AIM All-Share index was down 0.64% at 1,065.41. In continental Europe, the CAC-40 finished 0.29% lower at 5,488.55 whilst the DAX was down 0.59% at 13,202.90.

Wall Street
Last night in New York, the Dow Jones added 0.81% to close at 25,574.73. The S&P-500 gained 0.70% to end at 2,767.56 and the Nasdaq closed %0.81% higher at 7,211.78.

In Asian markets this morning, the Nikkei 225 was down 81.08 points (0.34%) at 23,629.35 and the Hang Seng was up 166.49 points (0.53%) at 31,286.88. Meanwhile, the Shanghai Composite was 3.09 points lower at 3,422.26.


In early trade today, WTI  crude was down 0.28% at $63.62 per barrel and Brent was unchanged at $69.26 per barrel.



Government to hold pensions talks with Carillion
The government will meet Carillion and the Pensions Regulator on Friday to discuss the giant services and construction company's deficit. Carillion, which is one of the government's biggest contractors, is struggling under £1.5bn of debt, including a pension shortfall of £587m. The company held talks with its lenders and advisers in London on Wednesday. However, no announcement has been made on a business plan to secure its future. Carillion is the UK's second largest construction company and employs 43,000 people globally. It has been awarded contracts to build part of £56bn High Speed 2 railway, including the first phase of the line which will run between London and Birmingham and is scheduled to open in 2026. Carillion also manages nearly 900 schools, provides services to the NHS and works with National Grid.

Source: BBC News

Company news


Armadale Capital (LON:ACP)  2.25p – Speculative Buy
Armadale announced that it has entered into a heads of agreement (HOA) with Weghsteen Capital (on behalf of Radismore Limited) to sell its 80% interest in the Mpokoto Gold project in the Katanga Province of the DRC for a total consideration of US$562,500 (payable in cash over three stages) and a 1.5% production royalty. The HOA is subject to execution of a formal binding agreement, which is expected in Q1 2018. Radismore has stated that it is committed to advancing Mpokoto to gold production within two years. Mpokoto has a current resource estimate of 678,000oz grading 1.45g/t Au.

Our view: Selling its non-core investments allows Armadale to focus on fast-tracking its Mahenge Liandu graphite project in Tanzania while retaining an interest in any future production at Mpokoto without the risks associate with development and mining. Given that mining licences are already in place, production from Mpokoto is feasible within two years. Armadale continues to develop the Mahenge Liandu graphite project with results from a scoping study and a drilling program aimed at increasing the current resource expected in Q1 and Q2 2018, respectively. In the meantime, we maintain a Speculative Buy rating on the stock.

Beaufort Securities acts as a corporate broker to Armadale Capital PLC

 Ferrum Crescent (LON:FCR0.11p – Speculative Buy

FCR, the European lead-zinc explorer, announced that Colin Bird has been appointed to the Board as a Non-Executive Director and Chairman with immediate effect. Mr Bird is a chartered mining engineer with extensive multi-commodity mine management experience in Africa, Europe, Latin America and the Middle East. The Company also stated that it is on schedule to publish a maiden JORC (2012) compliant resource estimate for its Toral lead-zinc and associated metals project in Spain by the end of January 2018.

Our view: The above announcement is good news for FCR as it continues to strengthen its Board with a well-known mining engineer and entrepreneur while it focuses on the develop of the Toral lead-zinc (and associated metals) project. We look forward to the maiden JORC (2012) compliant resource estimate in the coming weeks. In the meantime, we maintain our Speculative Buy on the stock.

Beaufort Securities acts as a corporate broker to Ferrum Crescent plc

 Prospex Oil & Gas (LON:PXOG) 0.60p – Speculative Buy

Prospex has announced that flow testing has commenced at its recently drilled onshore gas well in Italy (it has a 17% interest). The operator advises that flow test results will be available within 7 days. This morning’s RNS also notes that the Bainet gas discovery in Romania (50% owned by Prospex) is due to come online in 2Q17, while the most recent Spanish gas investment (830 bcf prospective) is being advanced as well.

Our view: There’s plenty of positive news flow coming out of Prospex. Operating has proven very straightforward in both Italy and Romania which keeps the company lean, effective and interesting. We look forward to the flow test results, potentially end of next week. We have a Speculative Buy recommendation.

Beaufort Securities acts as a corporate broker to Prospex Oil & Gas plc

ValiRx (LON:VAL) 4.82p – Speculative Buy
ValiRx yesterday announced that it has received a notice of allowance for the US patent application for VAL201. The patent covers the molecule and use of compounds in pharmaceutically acceptable products. ValiRx’s CEO, Dr Satu Vainikka, commented “This US allowance means we can proceed to strengthen the VAL201 patent portfolio and, once granted, will provide ValiRx with patent protection in all its largest commercial markets globally. ValiRx looks forward optimistically to its future prospects”.

Our view: A positive news from ValiRx, moving it step closer to patent grant in the US for VAL201. The patent has already been granted in the UK, Japan and Australia while Europe also pending a grant. There are also patent applications currently pending in many other territories. ValiRx recently received an approval from the UK Medicines and Healthcare Products Regulatory Agency and the Research Ethics Committee to substantially increase the dose of VAL201 (Phase I/II) in patients with locally advanced or metastatic prostate cancer and other advanced solid tumours to observe its full therapeutic potential. VAL201 is expected to be advantageous over other therapies as it does not involve androgen hormone deprivation, therefore fewer side effects associated to it. No dose limiting toxicity or any serious adverse events has been observed to date. According to GlobalData, the market value for prostate cancer is growing and expected to reach US$8.2bn in 2023. We reiterates our Speculative Buy rating on the shares.

Beaufort Securities acts as corporate broker to ValiRx Plc


Important Risk Warnings and Disclaimers 

This report is published by Beaufort Securities Ltd ("Beaufort Securities"). Beaufort Securities Ltd is Authorised and Regulated by the Financial Conduct Authority and is a Member of the London Stock Exchange. 


This document is not an offer to buy or sell any security or currency. This document does not provide you with individually tailored investment advice. It has been prepared without regard to the your financial circumstances and objectives The appropriateness of a particular investment or currency will depend on your individual circumstances and objectives. The investments and shares referred to in this document may not be suitable for you. 

This research is non-independent and is classified as a Marketing Communication under FCA rules. As such it has not been prepared in accordance with legal requirements designed to promote independence of investment research and it is not subject to the prohibition on dealing ahead of the dissemination of investment research in COBS 12.2.5. However Beaufort Securities has adopted internal procedures which prohibit analysts from dealing ahead of non-independent research, except for legitimate market making and fulfilling clients' unsolicited orders. 

By receiving this document, you will not be deemed a client or provided with the protections afforded to clients of Beaufort Securities. When distributing this document, Beaufort Securities is not acting for you and will not be responsible for providing advice to you in relation to this document. Accordingly, Beaufort Securities will not be responsible to you for providing the protections afforded to its clients. 

Beaufort Securities may effect transactions in shares mentioned herein and may take proprietary trading positions in those shares, and may receive remuneration for the publication of its research and for other services. Beaufort Securities may be a shareholder in any of the companies mentioned in this report. Accordingly, this document may not be considered as objective or impartial. Additionally, information may be available to Beaufort Securities or the Group, which is not reflected in this material. The remuneration of the author of this report is not tied to the recommendations on any shares mentioned nor to the any transactions undertaken by Beaufort Securities or any affiliate company. Further information on Beaufort Securities' policy regarding potential conflicts of interest in the context of investment research and Beaufort Securities' policy on disclosure and conflicts in general are available on request. Please refer to 

Past performance is not a guarantee of future performance. Investments may go down in value as well as up and you may not get back the full amount invested. The listing requirements for securities listed on AIM or the ICAP Securities & Derivatives Exchange are less demanding and trading in them may be less liquid than main markets. This may make it more difficult to buy and sell these securities. 


This document includes certain statements, estimates, and projections with respect to the anticipated future performance of securities listed on stock exchanges and as to the market for these shares. Such statements, estimates, and projections are based on information that we consider reliable and may reflect various assumptions made concerning anticipated economic developments, which have not been independently verified and may or may not prove correct. No representation or warranty is made as to the accuracy of such statements, estimates, and projections or as to its fitness for the purpose intended and it should not be relied upon as such. Opinions expressed are our current opinions as of the date appearing on this material only and may change without notice. Other third parties may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views, and analytical methods of the analysts who prepared them. This report has not been disclosed to any of the companies mentioned herein prior to its publication. 

This document is based on information Beaufort Securities has received from publicly available reports and industry sources. Beaufort Securities may not have verified all of this information with third parties. Neither Beaufort Securities nor its advisors, directors or employees can guarantee the accuracy, reasonableness or completeness of the information received from any sources consulted for this publication, and neither Beaufort Securities nor its advisors, directors or employees accepts any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by the applicable law). You should not rely on this document and should not use it substitution for the exercise of the independent judgment of yourself or your adviser. 

The information contained in this document is confidential and is solely for use of those persons to whom it is addressed and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. Other persons who receive this document should not rely on it. Beaufort Securities, its directors, officers and employees may have positions in the securities mentioned herein.


© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use